Vascular Disrupting Agents in Clinical Development

Overview

Journal Br J Cancer

Specialty Oncology

Date 2007 Mar 22

PMID 17375046

Citations 76

Authors

P Hinnen

F A L M Eskens

Affiliations

Soon will be listed here.

Abstract

Growth of human tumours depends on the supply of oxygen and nutrients via the surrounding vasculature. Therefore tumour vasculature is an attractive target for anticancer therapy. Apart from angiogenesis inhibitors that compromise the formation of new blood vessels, a second class of specific anticancer drugs has been developed. These so-called vascular disrupting agents (VDAs) target the established tumour vasculature and cause an acute and pronounced shutdown of blood vessels resulting in an almost complete stop of blood flow, ultimately leading to selective tumour necrosis. As a number of VDAs are now being tested in clinical studies, we will discuss their mechanism of action and the results obtained in preclinical studies. Also data from clinical studies will be reviewed and some considerations with regard to the future development are given.

Citing Articles

Targeting the tumour vasculature: from vessel destruction to promotion.

Guelfi S, Hodivala-Dilke K, Bergers G Nat Rev Cancer. 2024; 24(10):655-675.

PMID: 39210063 DOI: 10.1038/s41568-024-00736-0.

Multi-parametric investigations on the effects of vascular disrupting agents based on a platform of chorioallantoic membrane of chick embryos.

Chen L, Wang M, Feng Y, Gao L, Yu J, Geng L Quant Imaging Med Surg. 2024; 14(2):1729-1746.

PMID: 38415159 PMC: 10895113. DOI: 10.21037/qims-23-1065.

3-D Super-Resolution Ultrasound Imaging for Monitoring Early Changes in Breast Cancer after Treatment with a Vascular-Disrupting Agent.

Oezdemir I, Li J, Song J, Hoyt K IEEE Int Ultrason Symp. 2024; 2021.

PMID: 38351971 PMC: 10863700. DOI: 10.1109/IUS52206.2021.9593426.

Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context.

Czapla J, Drzyzga A, Matuszczak S, Cichon T, Rusin M, Jarosz-Biej M Front Oncol. 2023; 13:1249524.

PMID: 37655095 PMC: 10465696. DOI: 10.3389/fonc.2023.1249524.

The Development of HDAC and Tubulin Dual-Targeting Inhibitors for Cancer Therapy.

Nie J, Wu H, Luan Y, Wu J Mini Rev Med Chem. 2023; 24(5):480-490.

PMID: 37461341 DOI: 10.2174/1389557523666230717110255.

References

Chaplin D, Dougherty G . Tumour vasculature as a target for cancer therapy. Br J Cancer. 1999; 80 Suppl 1:57-64. View

Tozer G, Prise V, Wilson J, Locke R, Vojnovic B, Stratford M . Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 1999; 59(7):1626-34. View

Siemann D, Bibby M, Dark G, Dicker A, Eskens F, Horsman M . Differentiation and definition of vascular-targeted therapies. Clin Cancer Res. 2005; 11(2 Pt 1):416-20. View

Bilenker J, Flaherty K, Rosen M, Davis L, Gallagher M, Stevenson J . Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res. 2005; 11(4):1527-33. DOI: 10.1158/1078-0432.CCR-04-1434. View

de Jonge M, van der Gaast A, Planting A, van Doorn L, Lems A, Boot I . Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res. 2005; 11(10):3806-13. DOI: 10.1158/1078-0432.CCR-04-1937. View

Vincent L, Kermani P, Young L, Cheng J, Zhang F, Shido K . Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest. 2005; 115(11):2992-3006. PMC: 1253622. DOI: 10.1172/JCI24586. View

Shi W, Siemann D . Preclinical studies of the novel vascular disrupting agent MN-029. Anticancer Res. 2005; 25(6B):3899-904. View

van Heeckeren W, Bhakta S, Ortiz J, Duerk J, Cooney M, Dowlati A . Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?. J Clin Oncol. 2006; 24(10):1485-8. DOI: 10.1200/JCO.2005.04.8801. View

Beerepoot L, Radema S, Witteveen E, Thomas T, Wheeler C, Kempin S . Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol. 2006; 24(10):1491-8. DOI: 10.1200/JCO.2005.02.7458. View

10.

Hande K, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H . The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res. 2006; 12(9):2834-40. DOI: 10.1158/1078-0432.CCR-05-2159. View

11.

Ramaswamy B, Elias A, Kelbick N, Dodley A, Morrow M, Hauger M . Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res. 2006; 12(10):3124-9. DOI: 10.1158/1078-0432.CCR-05-2603. View

12.

Greystoke A, Blagden S, Thomas A, Scott E, Attard G, Molife R . A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. Ann Oncol. 2006; 17(8):1313-9. DOI: 10.1093/annonc/mdl097. View

13.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

14.

Motzer R, Hutson T, Tomczak P, Michaelson M, Bukowski R, Rixe O . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2):115-24. DOI: 10.1056/NEJMoa065044. View

15.

Escudier B, Eisen T, Stadler W, Szczylik C, Oudard S, Siebels M . Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356(2):125-34. DOI: 10.1056/NEJMoa060655. View

16.

Cooney M, Radivoyevitch T, Dowlati A, Overmoyer B, Levitan N, Robertson K . Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res. 2004; 10(1 Pt 1):96-100. DOI: 10.1158/1078-0432.ccr-0364-3. View

17.

Schoffski P, Thate B, Beutel G, Bolte O, Otto D, Hofmann M . Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol. 2004; 15(4):671-9. DOI: 10.1093/annonc/mdh141. View

18.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

19.

Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-6. DOI: 10.1056/NEJM197111182852108. View

20.

Denekamp J . Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer. 1982; 45(1):136-9. PMC: 2010961. DOI: 10.1038/bjc.1982.16. View